About NALCN channel auxiliary factor 2
NALCN channel auxiliary factor 2 (NALF2) is a protein
from Homo sapiens identified by UniProt accession
O75949, 472 residues long.
MolForge cross-references it against 0 known binders and
20 disease associations.
Target properties
| Protein name | NALCN channel auxiliary factor 2 |
| UniProt accession | O75949 |
| Gene | NALF2 |
| Organism | Homo sapiens |
| Length | 472 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (20)
Diseases linked to this target (Open Targets).
- non-small cell lung carcinoma · score 0.03
- Tetralogy of Fallot · score 0.03
- chronotype measurement · score 0.03
- actinic keratosis · score 0.01
- Ataxia-telangiectasia · score 0.01
- Neurodevelopmental delay · score 0.01
- ulcerative colitis · score 0.01
- systemic lupus erythematosus · score 0.01
- neoplasm · score 0.00
- Granulomatosis with Polyangiitis · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O75949-F1 | alphafold | PREDICTED | 63.37 | — |
Amino-acid sequence (472 residues)
MFRGAWMWPG KDAAALTICC CCCCWAPRPS DKPCADSERA QRWRLSLASL LFFTVLLADH LWLCAGARPR ARELSSAMRP PWGAGRERQP VPPRAVLPLP PPPPGEPSAP PGTCGPRYSN LTKAAPAAGS RPVCGGVPEP TGLDAACTKL QSLQRLFEPT TPAPPLRPPD SLSRAPAEFP SAKKNLLKGH FRNFTLSFCD TYTVWDLLLG MDRPDSLDCS LDTLMGDLLA VVASPGSGAW EACSNCIEAY QRLDRHAQEK YDEFDLVLHK YLQAEEYSIR SCTKGCKAVY KAWLCSEYFS VTQQECQRWV PCKQYCLEVQ TRCPFILPDN EEMVYGGLPG FICTGLLDTS PKRLETKCCD VQWVSCEAKK KKFKESEAPK THQQQFHHSY FHHYHQQYHH YHPHHDPPGR VSNKPALLPV SGGSRLSPSR IRLCVLVLML LHTVVSFSSN QGGGGLGLET LPALEEGLTR EE
Explore NALCN channel auxiliary factor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets